Overview

Clinical Efficacy and Safety Evaluation of Irbesartan and Amlodipine Combined Therapy in Essential Hypertension Patients

Status:
Recruiting
Trial end date:
2023-02-01
Target enrollment:
0
Participant gender:
All
Summary
The purpose of this study is to evaluate efficacy and safety of Irbesartan and Amlodipine combined therapy in patients with essential hypertension inadequately controlled on Irbesartan monotherapy
Phase:
Phase 3
Accepts Healthy Volunteers?
No
Details
Lead Sponsor:
Handok Inc.
Treatments:
Amlodipine
Irbesartan
Criteria
Inclusion Criteria:

- Patients who are 19 years or older on screening

- Signed informed consent

- Patients with Essential Hypertension

- Other inclusion applied

Exclusion Criteria:

- Orthostatic hypotension

- Other exclusion applied